• Home
  • News
  • Fortune 500
    • Fortune Global 500
    • Fortune 500 Europe
    • Fortune China 500
    • Fortune SEA 500
    • Great Place to Work
  • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Success
    • Future of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Home
  • News
  • FORTUNE 500
    • FORTUNE 500
    • FORTUNE SEA 500
    • Fortune 500 Europe
    • Fortune Global 500
    • Fortune China 500
    • Great Place to Work
  • Tech
    • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Banking
    • Investing
    • Crypto
  • Leadership
    • Leadership
    • Success
    • Future of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Rankings
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Asia
  • Europe
  • Analytics

Rene Vollgraaff

  • A healthcare worker administers a SINOVAC Covid-19 vaccine on a minor during the Numolux/SINOVAC Paediatric Covid-19 Vaccine Clinical Trial at the Sefako Makgatho Health Sciences University in Pretoria, on September 10, 2021. – The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac against confirmed symptomatic COVID-19 cases in children and adolescents aged 6 months to 17 years. Efficacy will also be evaluated against hospitalization and severe COVID-19 cases. The study worldwide will enroll 14 000 children and adolescents in various pediatric age group cohorts across 5 countries (South Africa, Chile, Philippines, Malaysia and Kenya). (Photo by Phill Magakoe / AFP) (Photo by PHILL MAGAKOE/AFP via Getty Images)Health

    South Africa could become COVID ‘mutation factory’ because of large HIV-infected population, scientists say

    By Rene Vollgraaff, Antony Sguazzin, and others
    Rankings
    • 100 Best Companies
    • Fortune 500
    • Global 500
    • Fortune 500 Europe
    • Most Powerful Women
    • Future 50
    • World’s Most Admired Companies
    • See All Rankings
    Sections
    • Finance
    • Leadership
    • Success
    • Tech
    • Asia
    • Europe
    • Environment
    • Fortune Crypto
    • Health
    • Retail
    • Lifestyle
    • Politics
    • Newsletters
    • Magazine
    • Features
    • Commentary
    • MPW
    • CEO Initiative
    • Conferences
    • Personal Finance
    • Education
    Customer Support
    • Frequently Asked Questions
    • Customer Service Portal
    • Privacy Policy
    • Terms of Use
    • Single Issues for Purchase
    • International Print
    Commercial Services
    • Advertising
    • Fortune Brand Studio
    • Fortune Analytics
    • Fortune Conferences
    • Business Development
    About Us
    • About Us
    • Editorial Calendar
    • Press Center
    • Work at Fortune
    • Diversity and Inclusion
    • Terms and Conditions
    • Site Map

    © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.